POLUS BioPharm Inc.
KRX
✓Strengths
No standout strengths flagged by the automated checks.
!Watch-points
- Higher leverage: debt-to-equity of 1.32 is above 1.
- Return on equity is on the lower side at -1%.
- Return on capital employed is on the lower side at -1.6%.
- The company reported a net loss in the latest period.
- Current ratio of 0.13 is below 1, so current liabilities exceed current assets.
- Sales growth has been slow over five years (about -94% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-1.14
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
3 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Book Value₩ 1,400.74
ROCE-1.55%
ROE-0.95%
Debt to Equity1.32
Current Ratio0.13
EPS₩ -13.00
PAT Margin-1821.71%
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity